Quick Answer
Orchestra BioMed Holdings, Inc. reported Operating Income Loss of -$51.81 million for the year ending 2025.
- Orchestra BioMed Holdings, Inc. showed an increase of +19.4% in Operating Income Loss from 2024 to 2025.
- This data is from Orchestra BioMed Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: -$15.2 thousand | Q3 2020: -$68.6 thousand | Q1 2021: -$111.9 thousand | Q2 2021: -$96.3 thousand | Q3 2021: -$94.4 thousand | Q1 2022: -$5.13 million | Q2 2022: -$7.63 million | Q3 2022: -$10.07 million | Q1 2023: -$11.55 million | Q2 2023: -$12.96 million | Q3 2023: -$14.52 million | Q1 2024: -$14.42 million | Q2 2024: -$16.86 million | Q3 2024: -$16.34 million | Q1 2025: -$18.92 million | Q2 2025: -$19.33 million | Q3 2025: -$20.31 million.
- Over the full 5 years of available data (2021 to 2025), Orchestra BioMed Holdings, Inc.'s Operating Income Loss has declined by 13,023.8%.
- Historical annual values: Fiscal year 2025: -$51.81 million | Fiscal year 2024: -$64.30 million | Fiscal year 2023: -$51.51 million | Fiscal year 2022: -$32.66 million | Fiscal year 2021: -$394.8 thousand.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: